Hepatocellular
carcinoma (HCC) is one of the leading causes of
cancer-related death worldwide. The destructive nature of the disease
makes it difficult for clinicians to manage the condition. Hence,
there is an urgent need to find new alternatives for HCC, as the role
of conventional cytotoxic drugs has reached a plateau to control HCC
associated mortality. Antioxidant compounds of plant origin with potential
anti-tumor effect have been recognized as alternate modes in cancer
treatment and chemoprevention. Resveratrol (RS) is a model natural
nonflavonoid drug known for its anti-cancer activity. However, its
clinical application is limited due to its poor bioavailability. The
current research work aims to formulate, optimize, and characterize
RS loaded cationic liposomes (RLs) for specific delivery in HCC. The
optimized liposomes formulation (RL5) was spherical with a vesicle
size (VS) of 145.78 ± 9.9 nm, ζ potential (ZP) of 38.03
± 9.12 mV, and encapsulation efficiency (EE) of 78.14 ±
8.04%. In vitro cytotoxicity studies in HepG2 cells
demonstrated an improved anti-cancer activity of RL5 in comparison
with free RS. These outcomes were supported by a cell uptake study
in HepG2 cells, in which RL5 exhibited a higher uptake than free RS.
Furthermore, confocal images of HepG2 cells after 3 and 5 h of incubation
showed higher internalization of coumarin 6 (C6) loaded liposomes
(CL) as compared to those of the free C6. Pharmacokinetic and pharmacodynamic
(prophylactic and therapeutic treatment modalities) studies were performed
in N-nitrosodiethylamine (NDEA-carcinogen) induced
HCC in rats. Pharmacokinetic evaluation of RL5 demonstrated increased
localization of RS in cancerous liver tissues by 3.2- and 2.2-fold
increase in AUC and Cmax, respectively, when compared to those of
the free RS group. A pharmacodynamic investigation revealed a significant
reduction in hepatocyte nodules in RL5 treated animals when compared
to those of free RS. Further, on treatment with RL5, HCC-bearing rats
showed a significant decrease in the liver marker enzymes (alanine
transaminase, alkaline phosphatase, aspartate transaminase, total
bilirubin levels, γ-glutamyl transpeptidase, and α-fetoprotein),
in comparison with that of the disease control group. Our findings
were supported by histopathological analysis, and we were first to
demonstrate that NDEA induced detrimental effect on rat livers was
successfully reversed with the treatment of RL5 formulation. These
results implied that delivery of RS loaded cationic liposomes substantially
controlled the severity of HCC and that they can be considered as
a promising nanocarrier in the management of HCC.